Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714514 · ClinicalTrials.gov registry record
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
A clinical trial of Kidney Transplantation in Highly Sensitized Patients, sponsored by Hansa Biopharma AB.
- Active
- Registry status
- 64
- Enrollment target
- 14
- Study locations
NCT05714514 is a study of Kidney Transplantation in Highly Sensitized Patients that is active but no longer recruiting, run by Hansa Biopharma AB. The registered enrollment target is 64 participants. The trial reports 14 study locations across 11 states.
The verdict
NCT05714514, a study of Kidney Transplantation in Highly Sensitized Patients, is active but no longer recruiting, sponsored by Hansa Biopharma AB.
- ACTIVE NOT RECRUITING
- Registry status
- 64 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Conditions Studied
Interventions
- DRUG Imlifidase administered in the ConfIdeS study
- OTHER Best available treatment administered in the ConfIdeS study
Study Locations (14)
Illinois
- Northwestern University, Dept. General Surgery, Div. Transplantation - Chicago
- University of Chicago, Department of Surgery, Clinical Research Center - Chicago
New York
- New York University (NYU) Langone Transplant Institute, NYU Langone Health - New York
- Columbia University - New York
Texas
- Houston Methodist Hospital - Houston
- Methodist Hospital Specialty and Transplant - San Antonio
Alabama
- University of Alabama at Birmingham (UAB) Hospital - Birmingham
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- John Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05714514
The ClinicalTrials.gov registry entry for NCT05714514 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplantation in Highly Sensitized Patients appearing as the primary indexed condition, and to 2 interventions - of which Imlifidase administered in the ConfIdeS study is the first listed.
NCT05714514 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Illinois, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05714514 about?
NCT05714514 is a clinical study titled "Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys". The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, N...
What is the current status of trial NCT05714514?
This trial is currently active not recruiting. The enrollment target is 64 participants. The study started on 2023-04-21. Estimated completion is 2029-12-31.
What conditions does trial NCT05714514 study?
This clinical trial studies the following conditions: Kidney Transplantation in Highly Sensitized Patients.
What interventions are being tested in trial NCT05714514?
The interventions under investigation include: Imlifidase administered in the ConfIdeS study (DRUG), Best available treatment administered in the ConfIdeS study (OTHER).
Who is sponsoring clinical trial NCT05714514?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714514 being conducted?
This trial has 14 study locations across Alabama, California, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation in Highly Sensitized Patients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.